Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GH Guardant Health Inc
- Stocks
- Healthcare
- NASDAQ: GH
Price (delayed)
$41.66
Market cap
$5.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.39
Enterprise value
$5.63B
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health
Highlights
The gross profit has grown by 30% YoY and by 6% from the previous quarter
Guardant Health's revenue has increased by 28% YoY and by 4.7% from the previous quarter
GH's equity has shrunk by 80% QoQ
Guardant Health's quick ratio has decreased by 26% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of GH
Market
Valuations
Earnings
Shares outstanding
123.89M
Market cap
$5.16B
Enterprise value
$5.63B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.28
Revenue
$774M
Gross profit
$474.77M
Operating income
-$454.95M
Net income
-$416.55M
EBIT
-$412.65M
EBITDA
-$370.74M
Free cash flow
-$304.87M
Per share
Balance sheet
Liquidity
EPS
-$3.39
EPS diluted
-$3.39
Free cash flow per share
-$2.46
Book value per share
-$2.03
Revenue per share
$6.25
TBVPS
$10.77
Total assets
$1.34B
Total liabilities
$1.6B
Debt
$1.28B
Equity
-$250.79M
Working capital
$701.27M
Debt to equity
-5.09
Current ratio
4.11
Quick ratio
4.07
Net debt/EBITDA
-1.28
Margins
Efficiency
Dividend
EBITDA margin
-47.9%
Gross margin
61.3%
Net margin
-53.8%
Operating margin
-58.8%
Return on assets
-27.9%
Return on equity
N/A
Return on invested capital
-23.1%
Return on capital employed
-36.9%
Return on sales
-53.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GH stock price
How has the Guardant Health stock price performed over time
Intraday
-0.14%
1 week
-5.43%
1 month
-4.69%
1 year
86.23%
YTD
36.37%
QTD
-2.21%
Financial performance
How have Guardant Health's revenue and profit performed over time
Revenue
$774M
Gross profit
$474.77M
Operating income
-$454.95M
Net income
-$416.55M
Gross margin
61.3%
Net margin
-53.8%
The company's operating margin rose by 33% YoY and by 2% QoQ
The gross profit has grown by 30% YoY and by 6% from the previous quarter
The net margin is up by 29% year-on-year and by 9% since the previous quarter
Guardant Health's revenue has increased by 28% YoY and by 4.7% from the previous quarter
Price vs fundamentals
How does GH's price correlate with its fundamentals
Growth
What is Guardant Health's growth rate over time
Valuation
What is Guardant Health stock price valuation
P/E
N/A
P/B
N/A
P/S
6.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.28
The EPS is up by 14% year-on-year and by 4.8% since the previous quarter
GH's equity has shrunk by 80% QoQ
The P/S is 64% below the 5-year quarterly average of 18.3 but 24% above the last 4 quarters average of 5.4
Guardant Health's revenue has increased by 28% YoY and by 4.7% from the previous quarter
Efficiency
How efficient is Guardant Health business performance
The return on sales is up by 30% year-on-year and by 9% since the previous quarter
GH's ROA is down by 8% year-on-year
Guardant Health's ROIC has decreased by 8% YoY but it has increased by 3.8% from the previous quarter
Dividends
What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GH.
Financial health
How did Guardant Health financials performed over time
Guardant Health's total assets is 16% less than its total liabilities
GH's current ratio is down by 31% year-on-year and by 12% since the previous quarter
Guardant Health's quick ratio has decreased by 26% YoY and by 13% from the previous quarter
GH's debt to equity has dropped by 126% year-on-year but it is up by 46% since the previous quarter
GH's equity has shrunk by 80% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.